Nose-to-brain delivery of octreotide acetate in situ gel for pituitary adenoma: Pharmacological and in vitro cytotoxicity studies.
Cytotoxicity study
Gamma scintigraphy
In situ gel
Intranasal administration
Octreotide acetate
Pituitary cancer
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Dec 2022
15 Dec 2022
Historique:
received:
20
07
2022
revised:
31
10
2022
accepted:
02
11
2022
pubmed:
10
11
2022
medline:
3
12
2022
entrez:
9
11
2022
Statut:
ppublish
Résumé
Octreotide acetate (OA), a potent octapeptide, is used in the treatment of pituitary adenoma. An approach has been made in the present research to formulate an OA-loaded intranasal in situ gel (OA-ISG) to target pituitary adenoma. To achieve the objective of the present work, OA-ISG was fabricated using cold method, and further optimization was done by 3
Identifiants
pubmed: 36351503
pii: S0378-5173(22)00927-9
doi: 10.1016/j.ijpharm.2022.122372
pii:
doi:
Substances chimiques
Octreotide
RWM8CCW8GP
Technetium
7440-26-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122372Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Chandrakant Kokare reports financial support was provided by All India Council for Technical Education.